Published in Medical Letter on the CDC and FDA, February 27th, 2005
On a generally accepted accounting principles (GAAP) basis, Chiron reported income from continuing operations of $60 million, or $0.32 per share, for the year ended December 31, 2004, compared to income from continuing operations of $220 million, or $1.15 per share, for the year ended December 31, 2003. Foreign exchange rates resulted in an approximate $0.07 decrease in pro forma earnings per share (EPS) and an approximate $0.08 decrease in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.